NEWS - 2009

Interface Biologics Expands Scientific Advisory Board

Toronto, Canada, October 19, 2009 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Board ("SAB").

MORE

Biomedical Polymer Is Proving to be a Powerful Infection Fighter that Protects Patients

Interface Biologics, Toronto, Ontario

Just about everyone on the planet will get a sliver of something in a finger at one time or another. Whether it is wood, metal, plastic or glass, if you don’t get it out, it soon becomes a painful mess of infection. Your body is just not meant to have foreign things and bad bacteria
inside it. Period.

Download Full Article (English PDF)

Un polymère biomédical devient un puissant allié dans la lutte contre les infections

Interface Biologics,Toronto, ON

À peu près tout le monde sur la planète recevra, un jour ou l’autre, un éclat de quelque chose dans le doigt. Qu’il soit de bois, de métal, de plastique ou de verre, si vous ne le retirez pas, votre doigt ne tardera pas à vous faire mal et à s’infecter. Votre organisme ne tolère tout simplement pas que des corps étrangers et de mauvaises bactéries y pénètrent, un point c’est tout.

Télécharger l'article complet (PDF français)

Antimicrobial-Infused Polymer Demonstrates Backbone

Bob Michaels

Implants often rely on antimicrobial coatings to prevent infections. But the release of antibacterial agents via diffusion from a biomaterial’s surface may not be the most effective approach for combating biofilm formation on implants. With this in mind, Interface Biologics (Toronto; www.interfacebiologics.com) is developing a technology platform that it claims will prevent biofilm formation more effectively than coatings, last longer in the body, and kill a broader spectrum of microbes.

MORE

Interface Biologics Appoints Arthur L. Rosenthal, Ph.D. to Board of Directors

Toronto, Canada, July 27, 2009 - For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today that experienced medical device executive, Arthur L. Rosenthal Ph.D., has been appointed to its Board of Directors.

MORE